Pharmaceutical Research and Manufacturers of America (PhRMA) news and information

The head of Europe's medicines regulator is digging in for a fight over data transparency after being stopped from releasing information on drugs from two U.S. companies by a court ruling.
FULL STORY »

Though they are not celebrating in public, executives and lawyers for pharmaceutical companies had to be happy last week after an appeals court in New York concluded that federal law does not prohibit sales reps from marketing drugs for uses not approved by the Food and Drug...
FULL STORY »

Drug and device makers fear the White House's budget-cutting plans will undermine legislation intended to improve the reviews of new products.
FULL STORY »

Virginia became the first state to lob its opposition to healthcare reform in March 2010 when lawmakers declared that no resident would be required to purchase health insurance.
FULL STORY »

Drugmakers were seen as the key group Democrats sought to win over as the White House crafted and pushed through the 2010 healthcare law, according to an investigation by House Republican staff.
FULL STORY »

Among all health industry groups with which the White House was negotiating deals leading up to passage of the 2010 healthcare law, drugmakers were seen by Washington Democrats as the key group, according to a yearlong investigation by House Republican staff.
FULL STORY »

A bill to reauthorize and expand the Food and Drug Administration's user-fee programs easily passed the House of Representatives 387-5.
FULL STORY »

An ongoing federal probe indicates there was a deal between the White House and PhRMA that bound both entities to certain commitments before Congress passed the healthcare reform law.
FULL STORY »

Although many providers and drug companies have frozen their compliance with a new federal payment reporting law until regulations are finalized, many devicemakers are busy preparing.
FULL STORY »

Only 13% of U.S. medical schools have a top-rated policy requiring faculty to disclose past or present financial ties with the pharmaceutical industry, even though a new federal law will soon require disclosures of such information publicly, the American Medical Student Association reports.
FULL STORY »